The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker.

IF 3.3 4区 医学 Q2 ONCOLOGY Breast Cancer : Targets and Therapy Pub Date : 2024-07-03 eCollection Date: 2024-01-01 DOI:10.2147/BCTT.S464161
Mehmet Emin Buyukbayram, Zekeriya Hannarici, Yakup Duzkopru, Aykut Turhan, Alperen Akansel Caglar, Pınar Coban Esdur, Mehmet Bilici, Salim Basol Tekin, Doğan Yazılıtaş
{"title":"The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker.","authors":"Mehmet Emin Buyukbayram, Zekeriya Hannarici, Yakup Duzkopru, Aykut Turhan, Alperen Akansel Caglar, Pınar Coban Esdur, Mehmet Bilici, Salim Basol Tekin, Doğan Yazılıtaş","doi":"10.2147/BCTT.S464161","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Hormone positive breast cancer is a tumor with high mortality. Combining antihormonal therapy with cyclin dependent kinase 4/6 inhibitors (CDK4/6i) has resulted in longer survival. The effect of inflammatory parameters such as c-reactive protein and c-reactive protein/lymphocyte ratio (CLR) on efficacy and survival in CDK4/6i treatment is unknown. In our study, we aimed to investigate the role of CLR and some parameters in predicting progression-free survival (PFS) with CDK4/6i.</p><p><strong>Methods: </strong>This retrospective cohort study included 78 patients with denovo and recurrent metastatic breast cancer treated with CDK4/6i. Cut off values for the prediction of mortality by various numerical parameter scores were performed by ROC Curve analysis. The effect of clinical variables, inflammatory and histopathological parameters on survival was analyzed by Kaplan-Meier method.</p><p><strong>Results: </strong>Neutrophil/lymphocyte ratio (NLR) and CLR were statistically significant in predicting mortality (p < 0.05). Ki67 and CLR were correlated with PFS. Age and CLR were correlated with OS (p < 0.05). CLR was statistically significant for both PFS (p = 0.022) and OS (p = 0.006).</p><p><strong>Conclusion: </strong>In patients with metastatic hormone-positive breast cancer using CDK4/6i, low CLR and low Ki67 were correlated with longer PFS duration.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"16 ","pages":"329-339"},"PeriodicalIF":3.3000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227876/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer : Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/BCTT.S464161","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Hormone positive breast cancer is a tumor with high mortality. Combining antihormonal therapy with cyclin dependent kinase 4/6 inhibitors (CDK4/6i) has resulted in longer survival. The effect of inflammatory parameters such as c-reactive protein and c-reactive protein/lymphocyte ratio (CLR) on efficacy and survival in CDK4/6i treatment is unknown. In our study, we aimed to investigate the role of CLR and some parameters in predicting progression-free survival (PFS) with CDK4/6i.

Methods: This retrospective cohort study included 78 patients with denovo and recurrent metastatic breast cancer treated with CDK4/6i. Cut off values for the prediction of mortality by various numerical parameter scores were performed by ROC Curve analysis. The effect of clinical variables, inflammatory and histopathological parameters on survival was analyzed by Kaplan-Meier method.

Results: Neutrophil/lymphocyte ratio (NLR) and CLR were statistically significant in predicting mortality (p < 0.05). Ki67 and CLR were correlated with PFS. Age and CLR were correlated with OS (p < 0.05). CLR was statistically significant for both PFS (p = 0.022) and OS (p = 0.006).

Conclusion: In patients with metastatic hormone-positive breast cancer using CDK4/6i, low CLR and low Ki67 were correlated with longer PFS duration.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
C反应蛋白/淋巴细胞比值(CLR)对接受CDK4/6抑制剂治疗的转移性乳腺癌患者PFS的影响:一种新型生物标志物
目的:激素阳性乳腺癌是一种死亡率很高的肿瘤。将抗激素疗法与细胞周期蛋白依赖性激酶 4/6 抑制剂(CDK4/6i)结合使用可延长患者的生存期。c反应蛋白和c反应蛋白/淋巴细胞比值(CLR)等炎症指标对CDK4/6i治疗的疗效和生存期的影响尚不清楚。我们的研究旨在探讨CLR和一些参数在预测CDK4/6i治疗的无进展生存期(PFS)中的作用:这项回顾性队列研究纳入了78名接受CDK4/6i治疗的新发和复发转移性乳腺癌患者。通过ROC曲线分析法得出了各种数字参数评分预测死亡率的临界值。采用 Kaplan-Meier 法分析了临床变量、炎症和组织病理学参数对生存率的影响:结果:中性粒细胞/淋巴细胞比率(NLR)和CLR在预测死亡率方面具有统计学意义(P < 0.05)。Ki67和CLR与PFS相关。年龄和CLR与OS相关(P < 0.05)。CLR对PFS(p = 0.022)和OS(p = 0.006)均有统计学意义:结论:在使用CDK4/6i的激素阳性转移性乳腺癌患者中,低CLR和低Ki67与较长的PFS时间相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
40
审稿时长
16 weeks
期刊最新文献
A Prospective Tumour Marker for Breast Cancer: YWHAB and Its Role in Promoting Oncogenic Phenotypes. The Clinical Study of Intratumoral and Peritumoral Radiomics Based on DCE-MRI for HER-2 Positive and Low Expression Prediction in Breast Cancer. Exploring the Complexity of Pan-Cancer: Gene Convergences and in silico Analyses. Comparison of Hematological Parameters and the Associated Factors Among Women with and without Breast Cancer: A Case-Control Study. A Novel Peroxisome-Related Gene Signature Predicts Breast Cancer Prognosis and Correlates with T Cell Suppression.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1